Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sustained release tablets containing cefaclor active component and preparation method thereof

A technology of cefaclor and active ingredients, which is applied in the field of cefaclor sustained-release tablets and its preparation, and can solve the problems of inconvenient medication for patients, large side effects, and unstable blood drug concentration

Active Publication Date: 2009-01-28
TIANJIN CENT PHARM CO LTD
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the many times of taking medicine of ordinary tablets and capsules, the side effects are large, and the phenomenon of patients’ missed doses is prone to occur, and the blood drug concentration is not stable, and the duration of action is short; injections are inconvenient for patients to take medicine; sustained-release capsules and osmotic pump dosage forms Although the above shortcomings are overcome, the production process is complicated and the equipment requirements are high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained release tablets containing cefaclor active component and preparation method thereof
  • Sustained release tablets containing cefaclor active component and preparation method thereof
  • Sustained release tablets containing cefaclor active component and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0107] Tablet prescription:

[0108] Specification: 125mg

[0109] Product name Quantity per tablet

[0110] Cefaclor 125.00mg

[0111] Hypromellose (4000 and 100,000 grades) 13.00mg

[0112] Acrylic resin No. II 3.00mg

[0113] Lactose 13.00mg

[0114] 75% ethanol solution 75.0ml

[0115] Magnesium Stearate 3.00mg

[0116] Total: 157.00mg

[0117] Coating prescription:

[0118] Specification 125mg

[0119] Product name Quantity per tablet

[0120] Hypromellose (4000 and 100,000 grades) 8.00mg

[0121] Titanium Dioxide 2.00mg

[0122] Talc powder 2.00mg

[0123] Tween-80 0.001ml

[0124] Diethyl phthalate 0.002ml

[0125] Preparation ethanol 134.40mg

[0126] Total: 12.000mg

example 2

[0128] Tablet prescription:

[0129] Specification: 125mg

[0130] Product name Quantity per tablet

[0131] Cefaclor 125.00mg

[0132] Hypromellose (grade 100,000) 13.00mg

[0133] Acrylic resin No. II 3.00mg

[0134] Lactose 13.00mg

[0135] 75% ethanol solution 75.0ml

[0136] Magnesium Stearate 3.00mg

[0137] Total: 157.00mg

[0138] Coating prescription:

[0139] Specification 125mg

[0140] Product name Quantity per tablet

[0141] Hypromellose (grade 100,000) 8.00mg

[0142] Titanium Dioxide 2.00mg

[0143] Talc powder 2.00mg

[0144] Tween-80 0.001ml

[0145] Diethyl phthalate 0.002ml

[0146] Preparation ethanol 134.40mg

[0147] Total: 12.000mg

example 3

[0149] Product name Quantity per tablet

[0150] Cefaclor 375.00mg

[0151] Hypromellose (grade 100,000) 40.00mg

[0152] Acrylic resin No. II 6.00mg

[0153] Lactose 80.00mg (60.00mg inside; 20.00mg outside)

[0154] Povidone K30 8.00mg

[0155] 50% ethanol solution 18.00mg

[0156] Magnesium Stearate 8.00mg

[0157] Total 517.00mg

[0158] Coating prescription:

[0159] Strength 375mg

[0160] Product name Quantity per tablet

[0161] Hypromellose (grade 100,000) 24.00mg

[0162] Titanium Dioxide 6.00mg

[0163] Talc powder 6.00mg

[0164] Tween-80 0.003ml

[0165] Diethyl phthalate 0.005ml

[0166] Preparation Ethanol 400.00mg

[0167] Total: 36.000mg

[0168] The preparation technology of 1-3 embodiment:

[0169] (1) Processing of raw and auxiliary materials: Cefaclor, hypromellose, acrylic resin II, and lactose were pulverized by a universal pulverizer.

[0170] (2) Pre-mixing: Add lactose, hydroxypropyl methylcellulose, acrylic resin No. II, and cefaclor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a sustained-release preparation containing the active ingredient of cefaclor, which consists of the cefaclor, acrylics II, slow release stroma of hydroxypropyl methylcellulose, cementing agent, loading agent and other supplementary materials; wherein, the proportion by weight among the cefaclor, the slow release stroma and the acrylics II is 1:0.1-1:0.01-0.1. After being taken, the cefaclor sustained-release tablets can be slowly and continuously released according to the requirements to maintain effective blood level, thus achieving the action of controlled release. The sustained-release preparation has the characteristics of lasting action, low toxic and side effect, few times for taking medicine, and utilizing the minimum dose to achieve the best healing efficacy; furthermore, blood concentration is stable, the incidence rate of untoward effect is reduced, and the sustained-release preparation is more applicable to the use of the patients.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and relates to an improved pharmaceutical dosage form of cefaclor, more specifically a cefaclor sustained-release tablet and a preparation method thereof. Background technique [0002] Cefaclor is a broad-spectrum semi-synthetic cephalosporin antibiotic. The activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococcus, viridans streptococcus and staphylococcus epidermidis is the same as that of cefadroxil, and the antibacterial effect against non-enzyme-producing staphylococcus aureus and pneumococcus is higher than that of cefadroxil 2 to 4 times stronger. The activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than cephalexin, similar to cefadroxil, and the activity against Proteus mirabilis, Salmonella and Shigella is stronger than cefadroxil . 2.9-8mg / L of this product can inhibit a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/545A61K9/22A61P31/04
Inventor 杨福桢庞东颖
Owner TIANJIN CENT PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com